Back to Search
Start Over
A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1–negative advanced or metastatic non–small-cell lung cancer (NSCLC).
- Source :
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS9139-TPS9139, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 164018419
- Full Text :
- https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS9139